Literature DB >> 16893142

Rebuttal: are drugs too expensive in Canada?

Joel Lexchin1, Russell Williams, Jean Marion.   

Abstract

Mesh:

Year:  2006        PMID: 16893142      PMCID: PMC1781091     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  12 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  Returns on research and development for 1990s new drug introductions.

Authors:  Henry Grabowski; John Vernon; Joseph A DiMasi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study.

Authors:  Muhammad Mamdani; David N Juurlink; Alex Kopp; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal:  BMJ       Date:  2004-05-11

4.  The effect of generic competition on the price of brand-name drugs.

Authors:  Joel Lexchin
Journal:  Health Policy       Date:  2004-04       Impact factor: 2.980

5.  Cost of innovation in the pharmaceutical industry.

Authors:  J A DiMasi; R W Hansen; H G Grabowski; L Lasagna
Journal:  J Health Econ       Date:  1991-07       Impact factor: 3.883

Review 6.  Pricing medicines: theory and practice, challenges and opportunities.

Authors:  Nigel Gregson; Keiron Sparrowhawk; Josephine Mauskopf; John Paul
Journal:  Nat Rev Drug Discov       Date:  2005-02       Impact factor: 84.694

7.  Do higher drug costs lead to better health?

Authors:  Barbara Mintzes; Joel Lexchin
Journal:  Can J Clin Pharmacol       Date:  2005-01-07

8.  Cash interests taint drug advice.

Authors:  Rosie Taylor; Jim Giles
Journal:  Nature       Date:  2005-10-20       Impact factor: 49.962

9.  Estimating the cost of new drug development: is it really 802 million dollars?

Authors:  Christopher P Adams; Van V Brantner
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

10.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

View more
  1 in total

1.  Middle ground.

Authors:  Peter Phillips
Journal:  Can Fam Physician       Date:  2006-10       Impact factor: 3.275

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.